Long-Term Outcomes After Infective Endocarditis After Transcatheter Aortic Valve Replacement


21 Ottobre Ott 2020 7 months ago
  • Bartorelli A

Infective endocarditis (IE) after transcatheter aortic valve replacement (TAVR) is a rare but life-threatening complication associated with a high rate of severe complications and in-hospital death.The high comorbidity burden of TAVR recipients along with an increased exposure to health care–associated procedures may explain, in part, the poorer clinical outcomes of this population. To date, most data on outcomes of IE after TAVR have been limited to short-term or midterm (1-year) follow-up. In this study, we sought to evaluate the long-term (>2 year) outcomes and prognostic factors in patients developing definite IE after TAVR who survived the index hospitalization.


Del Val D, Linke A, Abdel-Wahab M, Latib A, Ihlemann N, Urena M, Won-Keun K, Husser O, Herrmann HC, Nombela-Franco L, Cheema AN, Le Breton H, Stortecky S, Bartorelli AL, Sinning JM, Amat-Santos I, Munoz-Garcia A, Lerakis S, Gutiérrez-Ibanez E, Landt M, Tchetche D, Testa L, Eltchaninoff H, Livi U, Castillo JC, Chakravarty T, Webb JG, Barbanti M, Kodali S, de Brito FS Jr, Ribeiro HB, Miceli A, Fiorina C, Dato GMA, Rosato F, Serra V, Masson JB, Wijeysundera HC, Mangione JA, Ferreira MC, Lima VC, Colafranceschi AS, Abizaid A, Marino MA, Esteves V, Andrea JCM, Himbert D, Pellegrini C, Auffret V, Olivares P, Nietlispach F, Pilgrim T, Durand E, Lisko J, Makkar R, Alkhodair A, Søndergaard L, Mangner N, Crusius L, Holzhey D, Regueiro A, Rodés-Cabau J. Minimally Invasive Vs. Conventional Aortic Valve Replacement With Rapid-Deployment Bioprostheses. Circulation 2020 Oct 13;142(15):1497-1499. doi: 10.1161/CIRCULATIONAHA.120.047469.

Go to PubMed